Low-Cost Microdevices for Point-of-Care Testing

Chin, Curtis D.; Chin, Sau Yin; Laksanasopin, Tassaneewan; Sia, Samuel K.

doi:10.1007/978-3-642-29268-2_1

Cited by 47 publications

(26 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other examples include the mChip, a device that tests whole blood for HIV using a combined microfluidic and protein-based immunoassay approach [58], and the Ativa Micro Lab (Ativa Medical, St. Paul, MN, USA), which was recently shown to execute a number of distinct blood tests with the use of a single device [59][60][61]. One upcoming technology is Ativa's portable Micro Lab, which has the potential to perform up to 25 distinct blood tests utilizing its various disposable test cards for each test.…”

Section: Current Commercial Poc Technologiesmentioning

confidence: 99%

Surface enhanced Raman spectroscopy (SERS) for in vitro diagnostic testing at the point of care

et al. 2017

View full text Add to dashboard Cite

Point-of-care (POC) device development is a growing field that aims to develop low-cost, rapid, sensitive in-vitro diagnostic testing platforms that are portable, selfcontained, and can be used anywhere -from modern clinics to remote and low resource areas. In this review, surface enhanced Raman spectroscopy (SERS) is discussed as a solution to facilitating the translation of bioanalytical sensing to the POC. The potential for SERS to meet the widely accepted "ASSURED" (Affordable, Sensitive, Specific, Userfriendly, Rapid, Equipment-free, and Deliverable) criterion provided by the World Health Organization is discussed based on recent advances in SERS in vitro assay development. As SERS provides attractive characteristics for multiplexed sensing at low concentration limits with a high degree of specificity, it holds great promise for enhancing current efforts in rapid diagnostic testing. In outlining the progression of SERS techniques over the past years combined with recent developments in smart nanomaterials, high-throughput microfluidics, and low-cost paper diagnostics, an extensive number of new possibilities show potential for translating SERS biosensors to the POC.

show abstract

Section: Current Commercial Poc Technologiesmentioning

confidence: 99%

Surface enhanced Raman spectroscopy (SERS) for in vitro diagnostic testing at the point of care

et al. 2017

View full text Add to dashboard Cite

show abstract

“…309 Chin et al also provide a useful review of POC microdevices for clinical chemistry. 310 Additional tests capable of measuring pH and lactate have been previously discussed in the section on Multianalyte Detection and Monitoring.…”

Section: Diagnostics For Neonatal Healthmentioning

confidence: 99%

Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings

et al. 2017

View full text Add to dashboard Cite

Each day, approximately 830 women and 7,400 newborns die from complications during pregnancy and childbirth. Improving maternal and neonatal health will require bringing rapid diagnosis and treatment to the point of care in low-resource settings. However, to date there are few diagnostic tools available that can be used at the point of care to detect the leading causes of maternal and neonatal mortality in low-resource settings. Here we review both commercially available diagnostics and technologies that are currently in development to detect the leading causes of maternal and neonatal mortality, highlighting key gaps in development where innovative design could increase access to technology and enable rapid diagnosis at the bedside.

show abstract

“…The Spartan RX CYP2C19 System, developed by Spartan Bioscience Inc., is the first POC genetic testing system to receive the CE marking from the European regulatory health authorities [13]. The device measures 17 × 36 × 12 cm and weighs around 4.2 kg ( Figure 2) [14].…”

Section: Featuresmentioning

confidence: 99%

Point-of-Care Molecular Diagnostic Devices: An Overview

Chan

Todaro

et al. 2015

Pharmacogenomics

View full text Add to dashboard Cite

Point-of-care molecular diagnostic devices are a rapidly expanding market. A variety of technologies are being developed for DNA detection and amplification, mostly aiming to detect pathogens. Of the two devices for detection of human genetic variations, both focus on CYP2C19 and have obtained regulatory approval. Most other devices have not obtained US FDA approval and are still undergoing clinical trials. Most, if not all, devices in development require equipment to which disposable test cartridges are placed. Thus, they may not fulfill FDA's definition of being 'simple'. There is a clear need to develop completely disposable devices that do not require equipment maintenance, and to detect other genetic variants predictive of disease susceptibility and drug response.

show abstract

Low-Cost Microdevices for Point-of-Care Testing

Cited by 47 publications

References 72 publications

Surface enhanced Raman spectroscopy (SERS) for in vitro diagnostic testing at the point of care

Surface enhanced Raman spectroscopy (SERS) for in vitro diagnostic testing at the point of care

Point-of-care diagnostics to improve maternal and neonatal health in low-resource settings

Point-of-Care Molecular Diagnostic Devices: An Overview

Contact Info

Product

Resources

About